Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-anticipated GAAP loss. Management attributed the revenue momentum primarily to strong adoption in women’s health and oncology, with CEO Steven Leonard Chapman highlighting the rapid scale-up of the new Fetal Focus product and record growth in clinical oncology testing. The company noted that exceptional volume growth, especially in the closing weeks of the quarter, led to a temporary margin impact as more samples remained in process at quarter end, affecting cost recognition.

Is now the time to buy NTRA? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Natera’s Q1 Earnings Call

• Douglas Anthony Schenkel (Wolfe Research): Asked about the decision not to raise gross margin guidance further and whether one-time SG&A expenses affected spending discipline. CFO Michael Brophy explained the margin guidance reflects a cautious approach but sees room for upside due to clean unit economics and non-recurring SG&A charges.
• Daniel Gregory Brennan (TD Cowen): Questioned the unusually low percentage of tests recognized in revenue and the outlook for MolDx pan-cancer reimbursement. CEO Steven Leonard Chapman noted the received-to-reported ratio should normalize, and multiple cancer types are under Medicare review, with significant ASP upsides possible.
• Tycho W. Peterson (Jefferies): Inquired about Fetal Focus market share and competitive dynamics in women’s health, as well as Latitude’s expansion. Chapman highlighted strong sequential growth in women’s health and growing adoption of Latitude in cases where tissue is unavailable.
• Subhalaxmi Nambi (Guggenheim): Asked about rare disease product Zenith’s ramp and reimbursement risks. Chapman said Zenith is early in its launch but progressing well, with limited exposure to broader industry reimbursement challenges at this stage.
• Morgan Stanley Analyst: Probed cost implications for early cancer detection initiatives and Signatera’s growth dynamics. Brophy outlined that most R&D expenses for the FIND trial are now reflected in guidance, and commercialization costs will be phased in as volumes build, leveraging existing sales infrastructure.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will be monitoring (1) the pace and magnitude of Signatera’s launch and adoption in Japan, (2) interim and final data readouts from the FIND colorectal cancer early detection trial, and (3) progress on reimbursement expansion for additional cancer indications and improvements in average selling prices. Execution in these areas will be critical markers for sustained growth and profitability.

Natera currently trades at $195.98, down from $219.82 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.